Search Results
Results found for "James Hassard"
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Allostery and Biased Signaling Change the Game The most profound change in GPCR drug discovery is our
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
AlphaFold: A Game-Changer with Caveats One of the newest tools in the lab’s arsenal is AlphaFold , DeepMind
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
Inside Revvity’s GPCR Journey: How Decades of Discovery Shaped pHSense From HTRF to pHSense: The Long Game
- The Truth About GPCR Product Launches: Years in the Making
Their “aha” moment came when they ran a dose-response with Exendin-4 on GLP-1 receptors—and saw clean
- The Five Traps of Ignoring Kinetics
by offset rate, using rapid calcium assays Potency Is a Ratio of Rates Two ligands compete for the same That’s where Terry’s Corner changes the game.
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable That’s where Terry’s Corner changes the game.
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! ❄ Dec 2 - 8, 2024
Don't get left in the dust—upgrade now and keep your GPCR gossip game strong!
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
They’re kinetic game-changers —compounds that rewrite the relationship between ligand , receptor , and
- 📰 GPCR Weekly News, March 6 to 12, 2023
Industry News Professor Dame Carol Robinson Received 2023 ASMS John.B.Fenn Award Exscientia Announces Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR Fast Company has named
- 📰 GPCR Weekly News, September 4 to 10, 2023
Magazine's for Pioneering AI-Driven Drug Discovery Domain Therapeutics CEO Pascal Neuville to Discuss Game-Changing
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
That’s where Terry’s Corner changes the game.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Biased agonism is a phenomenon where different ligands acting on the same receptor trigger distinct signaling JAMA Internal Medicine, 2024. 184 (9): p. 1056-1064. 11. https://www.evaluate.com/thought-leadership/
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Terry Kenakin delivers a game-changing framework for teams grappling with the gap between in vitro potency
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
You assume your cofounder sees the same finish line you do. Here’s how it happens: 1️⃣ Duplicated effort 👉 Two teams think they’re building toward the same milestone They just need to understand what game they’re playing. Here’s the truth biotech founders miss. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’
- 📰 GPCR Weekly News, October 30 to November 4, 2023
GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial Andrew Hopkins Inducted into RSC BMCS Hall of Fame
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
That's right, you're about to level up your knowledge game!
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Jama. 2020;323(9):844-853. 7. DiMasi JA, Grabowski HG, Hansen RW.
